Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDC-MMAE
- Development stage
- Preclinical
- Lead developer
- Tezcat Biosciences
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
MDC-MMAE is a monobody-drug conjugate (MDC) designed to selectively target RAS-mutant cancers, specifically multiple myeloma, by exploiting the process of macropinocytosis. Developed by Tezcat Biosciences in collaboration with the NYU Grossman School of Medicine, the drug consists of a proprietary fibronectin-based scaffold (monobody) conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cathepsin-cleavable linker. Unlike traditional antibody-drug conjugates (ADCs), the monobody scaffold is engineered to be selectively internalized through macropinocytosis, a nutrient-scavenging pathway upregulated in oncogenic RAS-driven cells. This mechanism allows for targeted delivery of the toxin to RAS-mutant clones while sparing wild-type cells. Preclinical studies have demonstrated significant anti-tumor activity, including complete tumor regression in murine models, and a favorable safety profile with increased tolerable drug delivery compared to standard ADC-MMAE formulations.
- Other names
- monobody-drug conjugate-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MDC-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDC-MMAE.